Exosomes (Exosomes(The new favorite of the pharmaceutical industry)

Extracellular vesicles are double-layered lipid-membrane vesicles about 30-150 nanometers in size that carry growth factors and signaling factors such as biomolecules such as proteins, nucleic acids (DNA or RNA), sugars, and lipids with genetic messages, and penetrate into tissues, the bloodstream, and even cross the blood-brain barrier to remote cells. These vesicles are responsible for transmitting signals and instructions between cells, and have the function of triggering the regulation of subsequent cells. Previously little was known about these vesicles, but the awarding of the 2013 Nobel Prize in Biomedical Sciences to professors James E. Rothman, Randy W. Schekman, and Thomas C. Sudhof for their exceptional contributions to exosomes has initiated a vast amount of research around the globe, revealing that exosomes play a role in immune regulation, anti-inflammation, cellular proliferation, tissue repair, inhibition of apoptosis and tissue repair, as well as in the development of the cellular system, Inhibition of apoptosis and tissue fibrosis. It has even overturned the traditional stereotype that "nerves cannot be regenerated" and has become a new focus of the pharmaceutical industry.

Exosome medical use is estimated to have a market value of 5 years.5.13USD billion, compounded annual growth rate38%

Due to the aging of the global population, the demand for treatment of chronic, oncological and degenerative diseases continues to grow and remains unmet, resulting in the continued development of the emerging biopharmaceutical market. Benefiting from the Regenerative Medicine Advanced Therapy (RMAT) policy announced by the U.S. FDA, the accelerated trend of regenerative medicine and precision medicine is obvious. In the post-covid-19 era, the cell therapy and molecular diagnostic industries are optimistic about the development potential of exosomes, and the industry is investing in the development of exosomes. In the post-covid-19 era, the cell therapy and molecular diagnostic industries are optimistic about the development potential of exosomes, and the amount of investment in exosome-related companies will reach US$136.4 million in a single year in 2021, which is twice as much as that in 2020. The cumulative amount of international pharmaceutical companies' drug development collaborations has also exceeded US$5 billion. Currently, there are about 55 companies worldwide engaged in exosome research and development. It is estimated that the output value will reach US$513 million in 2026, with a compound annual growth rate of 38%, which is in a high growth period.

Figure 1: Global Exosomal Pharmaceuticals Market Production Value Estimates 2021-2026